<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24131712</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>88</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms.</ArticleTitle><Pagination><StartPage>72</StartPage><EndPage>81</EndPage><MedlinePgn>72-81</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01848-13</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) is a major causative agent of hand, food, and mouth disease, which frequently occurs in young children. Since there are 11 subgenotypes (A, B1 to B5, and C1 to C5) within EV71, an EV71 vaccine capable of protecting against all of these subgenotypes is desirable. We report here the vaccine potential and protective mechanism of two chimeric virus-like particles (VLPs) presenting conserved neutralizing epitopes of EV71. We show that fusions of hepatitis B core antigen (HBc) with the SP55 or SP70 epitope of EV71, designated HBcSP55 and HBcSP70, respectively, can be rapidly generated and self-assembled into VLPs with the epitopes displayed on the surface. Immunization with the chimeric VLPs induced carrier- and epitope-specific antibody responses in mice. Anti-HBcSP55 and anti-HBcSP70 sera, but not anti-HBc sera, were able to neutralize in vitro multiple genotypes and strains of EV71. Importantly, passive immunization with anti-HBcSP55 or anti-HBcSP70 sera protected neonatal mice against lethal EV71 infections. Interestingly, anti-HBcSP70 sera could inhibit EV71 attachment to susceptible cells, whereas anti-HBcSP55 sera could not. However, both antisera were able to neutralize EV71 infection in vitro at the postattachment stage. The divergent mechanism of neutralization and protection conferred by anti-SP70 and anti-SP55 sera is in part attributed to their respective ability to bind authentic viral particles. Collectively, our study not only demonstrates that chimeric VLPs displaying the SP55 and SP70 epitopes are promising candidates for a broad-spectrum EV71 vaccine but also reveals distinct mechanisms of neutralization by the SP55- and SP70-targeted antibodies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Xiaohua</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ku</LastName><ForeName>Zhiqiang</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qingwei</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaoli</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Jinping</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yunfang</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Liangliang</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Cong</LastName><ForeName>Yao</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Zhong</ForeName><Initials>Z</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017931">DNA Primers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017931" MajorTopicYN="N">DNA Primers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014771" MajorTopicYN="Y">Virion</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24131712</ArticleId><ArticleId IdType="pmc">PMC3911748</ArticleId><ArticleId IdType="doi">10.1128/JVI.01848-13</ArticleId><ArticleId IdType="pii">JVI.01848-13</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McMinn PC. 2002. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol. Rev. 26:91&#x2013;107. 10.1111/j.1574-6976.2002.tb00601.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-6976.2002.tb00601.x</ArticleId><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong SS, Yip CC, Lau SK, Yuen KY. 2010. Human enterovirus 71 and hand, foot and mouth disease. Epidemiol. Infect. 138:1071&#x2013;1089. 10.1017/S0950268809991555</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268809991555</ArticleId><ArticleId IdType="pubmed">20056019</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee TC, Guo HR, Su HJ, Yang YC, Chang HL, Chen KT. 2009. Diseases caused by enterovirus 71 infection. Pediatr. Infect. Dis. J. 28:904&#x2013;910. 10.1097/IFN.0b013e3181a41d63</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IFN.0b013e3181a41d63</ArticleId><ArticleId IdType="pubmed">20118685</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Qian Y, Wang S, Serrano JM, Li W, Huang Z, Lu S. 2010. EV71: an emerging infectious disease vaccine target in the Far East? Vaccine 28:3516&#x2013;3521. 10.1016/j.vaccine.2010.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.03.003</ArticleId><ArticleId IdType="pubmed">20304038</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Chang LY. 2010. Development of enterovirus 71 vaccines. Expert Rev. Vaccines 9:149&#x2013;156. 10.1586/erv.09.152</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erv.09.152</ArticleId><ArticleId IdType="pubmed">20109026</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Chow VT, Poh CL. 2007. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect. 9:1299&#x2013;1306. 10.1016/j.micinf.2007.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2007.06.002</ArticleId><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS. 2002. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20:895&#x2013;904. 10.1016/S0264-410X(01)00385-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(01)00385-1</ArticleId><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HF, Chang MH, Chiang BL, Jeng ST. 2006. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine 24:2944&#x2013;2951. 10.1016/j.vaccine.2005.12.047</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2005.12.047</ArticleId><ArticleId IdType="pubmed">16448730</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HL, Huang JY, Chu TW, Tsai TC, Hung CM, Lin CC, Liu FC, Wang LC, Chen YJ, Lin MF, Chen CM. 2008. Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine 26:2882&#x2013;2889. 10.1016/j.vaccine.2008.03.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.03.041</ArticleId><ArticleId IdType="pubmed">18450335</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, Poh CL. 2007. Identification of neutralizing linear epitopes from the VP1 capsid protein of enterovirus 71 using synthetic peptides. Virus Res. 125:61&#x2013;68. 10.1016/j.virusres.2006.12.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2006.12.005</ArticleId><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette A, Fikes J. 2003. Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr. Opin. Immunol. 15:461&#x2013;470. 10.1016/S0952-7915(03)00083-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0952-7915(03)00083-9</ArticleId><ArticleId IdType="pubmed">12900280</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudek NL, Perlmutter P, Aguilar MI, Croft NP, Purcell AW. 2010. Epitope discovery and their use in peptide based vaccines. Curr. Pharm. Des. 16:3149&#x2013;3157. 10.2174/138161210793292447</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138161210793292447</ArticleId><ArticleId IdType="pubmed">20687873</ArticleId></ArticleIdList></Reference><Reference><Citation>Pumpens P, Grens E. 1999. Hepatitis B core particles as a universal display model: a structure-function basis for development. FEBS Lett. 442:1&#x2013;6. 10.1016/S0014-5793(98)01599-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(98)01599-3</ArticleId><ArticleId IdType="pubmed">9923592</ArticleId></ArticleIdList></Reference><Reference><Citation>Schodel F, Peterson D, Hughes J, Wirtz R, Milich D. 1996. Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. presentation of foreign epitopes. J. Biotechnol. 44:91&#x2013;96. 10.1016/0168-1656(95)00118-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0168-1656(95)00118-2</ArticleId><ArticleId IdType="pubmed">8717391</ArticleId></ArticleIdList></Reference><Reference><Citation>Pumpens P, Borisova GP, Crowther RA, Grens E. 1995. Hepatitis B virus core particles as epitope carriers. Intervirology 38:63&#x2013;74</Citation><ArticleIdList><ArticleId IdType="pubmed">8666525</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira GA, Wetzel K, Calvo-Calle JM, Nussenzweig R, Schmidt A, Birkett A, Dubovsky F, Tierney E, Gleiter CH, Boehmer G, Luty AJ, Ramharter M, Thornton GB, Kremsner PG, Nardin EH. 2005. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Infect. Immun. 73:3587&#x2013;3597. 10.1128/IAI.73.6.3587-3597.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.73.6.3587-3597.2005</ArticleId><ArticleId IdType="pmc">PMC1111818</ArticleId><ArticleId IdType="pubmed">15908388</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardin EH, Oliveira GA, Calvo-Calle JM, Wetzel K, Maier C, Birkett AJ, Sarpotdar P, Corado ML, Thornton GB, Schmidt A. 2004. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect. Immun. 72:6519&#x2013;6527. 10.1128/IAI.72.11.6519-6527.2004</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.72.11.6519-6527.2004</ArticleId><ArticleId IdType="pmc">PMC523031</ArticleId><ArticleId IdType="pubmed">15501783</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z, Ye X, Huang X, Cai Y, Liu Q, Li Y, Su Z, Huang Z. 2013. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps. PLoS One 8:e57601. 10.1371/journal.pone.0057601</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0057601</ArticleId><ArticleId IdType="pmc">PMC3579802</ArticleId><ArticleId IdType="pubmed">23451250</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Yan K, Feng Y, Huang X, Ku Z, Cai Y, Liu F, Shi J, Huang Z. 2012. A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine 30:6642&#x2013;6648. 10.1016/j.vaccine.2012.08.071</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.08.071</ArticleId><ArticleId IdType="pubmed">22959985</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Guo MS, Lin FH, Hsiao KN, Chang KH, Chou AH, Wang YC, Chen YC, Yang CS, Chong PC. 2011. Purification and characterization of enterovirus 71 viral particles produced from Vero cells grown in a serum-free microcarrier bioreactor system. PLoS One 6:e20005. 10.1371/journal.pone.0020005</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0020005</ArticleId><ArticleId IdType="pmc">PMC3094384</ArticleId><ArticleId IdType="pubmed">21603631</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Huang X, Ku Z, Wang T, Liu F, Cai Y, Li D, Leng Q, Huang Z. 2013. Characterization of enterovirus 71 capsids using subunit protein-specific polyclonal antibodies. J. Virol. Methods 187:127&#x2013;131. 10.1016/j.jviromet.2012.09.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2012.09.024</ArticleId><ArticleId IdType="pubmed">23046991</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z, Santi L, Lepore K, Kilbourne J, Arntzen CJ, Mason HS. 2006. Rapid, high-level production of hepatitis B core antigen in plant leaf and its immunogenicity in mice. Vaccine 24:2506&#x2013;2513. 10.1016/j.vaccine.2005.12.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2005.12.024</ArticleId><ArticleId IdType="pubmed">16417953</ArticleId></ArticleIdList></Reference><Reference><Citation>Haq TA, Mason HS, Clements JD, Arntzen CJ. 1995. Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science 268:714&#x2013;716. 10.1126/science.7732379</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.7732379</ArticleId><ArticleId IdType="pubmed">7732379</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z, Shi J, Liu Q, Huang Z. 2012. Development of murine monoclonal antibodies with potent neutralization effects on enterovirus 71. J. Virol. Methods 186:193&#x2013;197. 10.1016/j.jviromet.2012.06.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2012.06.025</ArticleId><ArticleId IdType="pubmed">22771741</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J, Huang X, Liu Q, Huang Z. 2013. Identification of conserved neutralizing linear epitopes within the VP1 protein of coxsackievirus A16. Vaccine 31:2130&#x2013;2136. 10.1016/j.vaccine.2013.02.051</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.02.051</ArticleId><ArticleId IdType="pubmed">23499595</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanlandschoot P, Cao T, Leroux-Roels G. 2003. The nucleocapsid of the hepatitis B virus: a remarkable immunogenic structure. Antivir. Res. 60:67&#x2013;74. 10.1016/j.antiviral.2003.08.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2003.08.011</ArticleId><ArticleId IdType="pubmed">14638400</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, Hu YC. 2008. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26:1855&#x2013;1862. 10.1016/j.vaccine.2008.01.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.01.058</ArticleId><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, Li X, Yin W, Shen X, Porta C, Walter TS, Evans G, Axford D, Owen R, Rowlands DJ, Wang J, Stuart DI, Fry EE, Rao Z. 2012. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat. Struct. Mol. Biol. 19:424&#x2013;429. 10.1038/nsmb.2255</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2255</ArticleId><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirk K, Poh CL, Fecondo J, Pourianfar H, Shaw J, Grollo L. 2012. Cross-reactive neutralizing antibody epitopes against enterovirus 71 identified by an in silico approach. Vaccine 30:7105&#x2013;7110. 10.1016/j.vaccine.2012.09.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.09.030</ArticleId><ArticleId IdType="pubmed">23022400</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, Chang JY, Guo MS, Chow YH, Yang WS, Chang KH, Sia C, Chong P. 2011. Identification and characterization of a cross-neutralization epitope of enterovirus 71. Vaccine 29:4362&#x2013;4372. 10.1016/j.vaccine.2011.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.010</ArticleId><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>De Filette M, Fiers W, Martens W, Birkett A, Ramne A, Lowenadler B, Lycke N, Jou WM, Saelens X. 2006. Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 24:6597&#x2013;6601. 10.1016/j.vaccine.2006.05.082</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2006.05.082</ArticleId><ArticleId IdType="pubmed">16814430</ArticleId></ArticleIdList></Reference><Reference><Citation>De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A, Resch S, Fiers W. 2005. Universal influenza A vaccine: optimization of M2-based constructs. Virology 337:149&#x2013;161. 10.1016/j.virol.2005.04.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2005.04.004</ArticleId><ArticleId IdType="pubmed">15914228</ArticleId></ArticleIdList></Reference><Reference><Citation>Shingler KL, Yoder JL, Carnegie MS, Ashley RE, Makhov AM, Conway JF, Hafenstein S. 2013. The enterovirus 71 A-particle forms a gateway to allow genome release: a cryoEM study of picornavirus uncoating. PLoS Pathog. 9:e1003240. 10.1371/journal.ppat.1003240</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003240</ArticleId><ArticleId IdType="pmc">PMC3605244</ArticleId><ArticleId IdType="pubmed">23555253</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>